Business Context and Reporting Period
Company: Allogene Therapeutics, Inc. (ALLO)
Filing Type: Form 8-K (Current Report)
Date of Report: April 14, 2026
Event: Entry into an underwriting agreement for a public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key metrics related to the offering include:
- Shares Offered: 87,500,000 shares of common stock.
- Offering Price: $2.00 per share.
- Gross Proceeds: Approximately $175.0 million (before underwriting discounts and expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 13,125,000 additional shares.
- Expected Closing Date: April 16, 2026.
Note: The filing text does not provide current values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of a public equity offering. The company has moved from a proposed offering (announced April 13, 2026) to a priced offering (announced April 14, 2026). This transaction will significantly increase the company's cash position upon closing, subject to customary conditions.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: Net proceeds are intended for general corporate purposes, specifically including:
- Clinical trial expenses.
- Research and development (R&D) expenses.
- General and administrative expenses.
- Capital expenditures.
Risks and Forward-Looking Statements: The company notes that actual results may differ from expectations due to market conditions and the satisfaction of closing conditions. Investors are referred to the Annual Report on Form 10-K for the year ended December 31, 2025, for a comprehensive list of risk factors.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $175.0 million gross proceeds.
- Confirm whether the underwriters exercise the 30-day option for 13,125,000 additional shares.
- Review the specific underwriting discounts and commissions to calculate net proceeds.
- Check the Form 10-K filed on March 12, 2026, for the most recent liquidity position and cash burn rate prior to this offering.
- Monitor press releases for updates on the allocation of funds to specific clinical trials.